BD appoints two new directors with healthcare and tech expertise

FRANKLIN LAKES, N.J. - BD (Becton, Dickinson and Company) (NYSE:BDX) announced Monday the appointment of Robert "Robbie" Huffines and Jacqueline "Jacky" Wright to its board of directors, effective December 1, 2025. The medical technology company, which boasts a market capitalization of $54.91 billion and maintains a "GOOD" financial health score according to InvestingPro, continues to strengthen its leadership team.

Huffines brings over 30 years of healthcare investment banking experience, most recently serving as global chairman of investment banking at J.P. Morgan Chase & Co. He currently serves on the board of Insulet Corporation and previously was a director at Walgreens Boots Alliance until its sale in August 2025.

Wright joins with extensive technology leadership credentials, having most recently worked as the first chief technology and platform officer at McKinsey & Company. Her background includes senior roles at Microsoft Corporation, where she served as chief digital officer for U.S. Business, and a two-year appointment as chief information & digital officer at HM Revenue and Customs in the United Kingdom.

"Robbie and Jacky will further strengthen the BD board with deep expertise in health care, technology, digital transformation and artificial intelligence, as well as finance and capital markets," said Tom Polen, chairman, CEO and president of BD, according to the company's press release. The appointments come as BD continues to deliver solid financial performance, with annual revenue of $21.84 billion and revenue growth of 8.24% over the last twelve months. InvestingPro analysis indicates BD is currently trading below its Fair Value, presenting a potential opportunity for investors interested in the healthcare equipment sector.

The appointments continue BD's board refreshment efforts, with three new independent directors added in 2025. BD, which employs approximately 70,000 people worldwide, describes itself as a global medical technology company focused on improving medical discovery, diagnostics and care delivery.

Both new directors will begin their board service next month as the company continues its strategic focus as what it terms a "scaled pure-play innovative medical technology company."

In other recent news, Becton, Dickinson and Co. (BDX) released its fourth-quarter earnings for 2025, presenting a mixed financial performance. The company reported earnings per share (EPS) of $3.96, slightly surpassing the forecasted $3.92, which represents a 1.02% positive surprise. However, revenue figures did not meet expectations, coming in at $5.9 billion against the anticipated $5.91 billion. This slight miss in revenue forecasts may have contributed to market reactions despite the EPS beat. There were no significant mergers or acquisitions announced during this period. Additionally, there were no analyst upgrades or downgrades reported in the recent developments. Investors and analysts will likely be closely monitoring future earnings and revenue forecasts for further insights.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.